This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: St. Jude Children's Research Hospital. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Innovations by Andrew Huber in Small Molecule Degraders
Introduction
Andrew Huber is an accomplished inventor based in Collierville, TN (US). He has made significant contributions to the field of pharmacology through his innovative work on small molecule degraders. His research focuses on improving drug safety and efficacy, particularly in relation to the pregnane X receptor (PXR).
Latest Patents
Andrew Huber holds 1 patent for his invention titled "Small molecule degraders and fluorescent probes of PXR." This patent relates to compounds, compositions, and methods for degrading PXR protein. The invention aims to decrease adverse drug reactions associated with various therapeutic agents, including anticancer, antibacterial, non-steroidal anti-inflammatory, and anticonvulsant agents. The disclosed compounds also facilitate the identification of PXR ligands, enhancing the understanding of drug interactions.
Career Highlights
Andrew Huber is currently affiliated with St. Jude Children's Research Hospital, where he continues to advance his research in drug development and safety. His work is pivotal in addressing the challenges posed by adverse drug reactions, which can significantly impact patient outcomes.
Collaborations
Andrew collaborates with esteemed colleagues such as Taosheng Chen and Young-Hwan Jung. Their combined expertise fosters a productive research environment, leading to innovative solutions in the field of pharmacology.
Conclusion
Andrew Huber's contributions to the development of small molecule degraders represent a significant advancement in drug safety and efficacy. His innovative work continues to impact the medical field positively.